Showing 5851-5860 of 7934 results for "".
- China's NMPA Accepts Akeso’s NDA for Ebdarokimab in Moderate-to-Severe Plaque Psoriasishttps://practicaldermatology.com/news/chinas-nmpa-accepts-akesos-nda-for-ebdarokimab-in-moderate-to-severe-plaque-psoriasis/2461958/Akeso Inc.’s New Drug Application (NDA) for its fully human IgG1monoclonal antibody ebdarokimab (IL-12/lL-23, AK101) for the treatment of adults with moderate-to-severe plaque psoriasis has been accepted by the National Center for Drug Evaluation of the State Drug Administration of the
- Verrica Pharmaceuticals Update: Company Announces First Sale of YCANTH to FFF Enterpriseshttps://practicaldermatology.com/news/verrica-pharmaceuticals-update-company-announces-first-sale-of-ycanth-to-fff-enterprises/2461957/Verrica Pharmaceuticals Inc. announced the first commercial sale of YCANTH to its exclusive distributor, FFF Enterprises Inc. (FFF). “As one of the nation’s most trusted specialty pharmaceutical distributors, FFF is well positioned to help Verrica introduce YCANTH&trad
- Verrica Supports FDA’s Warning Letters to Retailers Selling Unapproved Molluscum Contagiosum Treatmentshttps://practicaldermatology.com/news/verrica-supports-fdas-warning-letters-to-retailers-selling-unapproved-molluscum-contagiosum-treatments/2461954/Verrica Pharmaceuticals Inc. supports the U.S. Food and Drug Administration’s (FDA’s) recent action against retailers and manufacturers of unapproved products for the treatment of molluscum contagiosum. “On the heels of the June 1, 2023 FDA warning to consumers not to
- Unpacking the AAD’s Updated Guidelines for Managing AD With Topical Therapies in Adultshttps://practicaldermatology.com/news/guideline-author-dr-robert-sidbury-talks-to-dermwire-about-the-new-recommendations/2461953/Despite the availability of systemic medication to treat atopic dermatitis (AD), topical treatments remain mainstays, and new ones have come to market in recent years. To keep pace with the changes, the American Academy of Dermatology (AAD) updated its 2014 guidelines for managing atopi
- Paradigm Therapeutics Acquires Late Stage "Breakthrough Therapy" for Treatment of All Subtypes of EBhttps://practicaldermatology.com/news/paradigm-therapeutics-acquires-late-stage-breakthrough-therapy-for-treatment-of-all-subtypes-of-eb/2461948/Paradigm Therapeutics Inc. now has the worldwide rights of SD-101, a topical whole-body treatment for all subtypes of Epidermolysis Bullosa (EB), from Amicus Therapeutics. Terms of the deal have not been disclosed. SD-101 received Rare Pediatric Disease designation&
- Dove Gives Back With the Dove Nature Regeneration Projecthttps://practicaldermatology.com/news/dove-gives-back-with-the-dove-nature-regeneration-project/2461947/Dove is introducing their Nature Regeneration Project, a new initiative to protect nature and tackle climate change. In partnership with the Rimba Collective, Dove will help protect and restore 123,000 acres of rainforest in Southeast Asia –an area 8x the size of&n
- Experts to Develop Human Skin Cell Atlashttps://practicaldermatology.com/news/experts-to-develop-human-skin-cell-atlas/2461944/A grassroots movement to establish a Human Skin Cell Atlas is underway, according to a review in the Journal of Investigative Dermatology. To perform its numerous functions and to maintain pr
- Business News: LEO Pharma to Acquire Timber Pharmaceuticalshttps://practicaldermatology.com/news/business-news-leo-pharma-to-acquire-timber-pharmaceuticals/2461943/LEO Pharma is set to acquire Timber Pharmaceuticals, Inc. The deal represents a total transaction value of up to $36 million with an initial upfront consideration of $14 million, and up to an additional $22.0 million in contingent value rights payable upon achievement o
- EMA Accepts LEO Pharma’s MAA for Delgocitinib Cream in Chronic Hand Eczemahttps://practicaldermatology.com/news/ema-accepts-leo-pharmas-maa-for-delgocitinib-cream-in-chronic-hand-eczema/2461942/The European Medicines Agency (EMA) has validated LEO Pharma’s marketing authorization application for delgocitinib cream, an investigational product and topical pan-Janus kinase (JAK) inhibitor for the treatment of adult patients with moderate to severe chronic hand eczema (CHE).
- La Roche-Posay Is the Official Sunscreen of the US Open for the Second Yearhttps://practicaldermatology.com/news/la-roche-posay-is-the-official-sunscreen-of-the-us-open-for-the-second-year/2461941/La Roche-Posay is continuing its partnership as the exclusive Official Sunscreen Partner of the US Open for the second year in a row. At the 2022 US Open, La Roche-Posay provided access to board-certified dermatologists to educate on sun safety and distributed 300,000 free sunscree